Target Information

Target General Infomation
Target ID
T54761
Former ID
TTDI02324
Target Name
Myelin basic protein
Gene Name
MBP
Synonyms
Myelin A1 protein; Myelin membrane encephalitogenic protein; MBP
Target Type
Clinical Trial
Disease Multiple scierosis [ICD9: 340; ICD10: G35]
Function
The classic group of MBP isoforms (isoform 4-isoform 14) are with PLP the most abundant protein components of the myelin membrane in the CNS. They have a role in both its formation and stabilization. The smaller isoforms might have an important role in remyelination of denuded axons in multiple sclerosis. The non- classic group of MBP isoforms (isoform 1-isoform 3/Golli-MBPs) may preferentially have a role in the early developing brain long before myelination, maybe as components of transcriptional complexes, and may also be involved in signaling pathways in T- cells and neural cells. Differential splicing events combined with optional post-translational modifications give a wide spectrum of isomers, with each of them potentially having a specialized function. Induces T-cell proliferation. {ECO:0000269|PubMed:8544862}.
BioChemical Class
Myelin basic protein
UniProt ID
P02686
Sequence
MGNHAGKRELNAEKASTNSETNRGESEKKRNLGELSRTTSEDNEVFGEADANQNNGTSSQ
DTAVTDSKRTADPKNAWQDAHPADPGSRPHLIRLFSRDAPGREDNTFKDRPSESDELQTI
QEDSAATSESLDVMASQKRPSQRHGSKYLATASTMDHARHGFLPRHRDTGILDSIGRFFG
GDRGAPKRGSGKDSHHPARTAHYGSLPQKSHGRTQDENPVVHFFKNIVTPRTPPPSQGKG
RGLSLSRFSWGAEGQRPGFGYGGRASDYKSAHKGFKGVDAQGTLSKIFKLGGRDSRSGSP
MARR
Drugs and Mode of Action
Drug(s) BHT-3009 Drug Info Phase 2 Multiple scierosis [521894]
NBI-5788 Drug Info Phase 2 Multiple scierosis [521426]
Binder NBI-5788 Drug Info [525908]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
WikiPathways MAPK Cascade
Structural Pathway of Interleukin 1 (IL-1)
Spinal Cord Injury
Glial Cell Differentiation
Neural Crest Differentiation
References
Ref 521426ClinicalTrials.gov (NCT00001781) Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS). U.S. National Institutes of Health.
Ref 521894ClinicalTrials.gov (NCT00382629) BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health.
Ref 525908NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65.
Ref 530290BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.